Skip to main content

Selectivity Assessment of Bioanalytical Assay

Selectivity studies, also known as specificity studies, are an integral part of bioanalytical assay validation. These studies determine whether the assay can accurately measure the analyte of interest in the presence of potentially interfering substances, ensuring that the assay is specific to the analyte being measured. Here's how selectivity studies are typically performed:

Selectivity Experiment Design: The study is designed to evaluate potential interference from endogenous substances, metabolites, degradation products, or other analytes that might be present in the sample matrix. Known interfering substances, if identified, are included in the study.

Sample Preparation: A blank matrix (typically the same type of matrix as the study samples, such as plasma or urine) is prepared. The blank matrix is spiked with the analyte of interest at a low concentration (LLOQ) to mimic the lower limit of quantification.

Interfering Substances: If known interfering substances are identified, they are spiked into the blank matrix either individually or in combination with the analyte of interest. Interfering substances might include endogenous compounds, metabolites, or concomitant medications.

Analysis: The spiked samples are then analyzed using the bioanalytical assay. The goal is to determine whether the presence of interfering substances affects the accurate measurement of the analyte.

Data Analysis: The data is analyzed to determine whether the presence of interfering substances results in significant changes in the measured analyte concentration. Statistical analysis may be used to assess the impact of interference.

Acceptance Criteria: Acceptance criteria are established based on regulatory guidelines or predefined criteria. The criteria define the extent to which interference can be tolerated without compromising the accuracy of the assay.

Interpretation: If interference is observed, the laboratory must assess the potential impact on the assay's reliability. Depending on the degree of interference, corrective actions may be taken. These actions could include adjusting the assay conditions, matrix purification, or applying mathematical corrections.

Documentation: The results of the selectivity study, including any observed interferences and the laboratory's response, are thoroughly documented. This documentation serves as a record of how the assay responds to potential interferences.

Example: Selectivity Assessment for Drug Y Assay

Background:

  • Drug Y is a new investigational compound intended for treating a specific medical condition.
  • The bioanalytical assay measures the concentration of Drug Y in human plasma samples.
  • The assay must demonstrate selectivity by accurately measuring Drug Y in the presence of potentially interfering substances commonly found in plasma.

Selectivity Assessment:


Sample Preparation:

  • Prepare a set of human plasma samples as blank matrix samples (no Drug Y or interfering substances).
  • Prepare spiked samples by adding Drug Y at the lower limit of quantification (LLOQ) concentration (e.g., 5 ng/mL) to human plasma.

Interfering Substances:

  • Identify known interfering substances that could be present in plasma (e.g., endogenous compounds, metabolites, concomitant medications).

Spiking Interfering Substances:

  • Prepare spiked samples by adding the interfering substances to blank plasma samples at relevant concentrations.

Analysis:

  • Analyze the spiked samples containing Drug Y alone, spiked samples containing both Drug Y and interfering substances, and blank plasma samples using the bioanalytical assay.

Calculation of Selectivity:

  • Calculate the response (peak area or signal) of Drug Y in the presence of interfering substances and compare it to the response of Drug Y alone.

Data Interpretation:

  • If the presence of interfering substances does not significantly affect the accuracy and precision of Drug Y measurement, the assay is considered selective.
  • Calculate the percent change in response due to interference and assess whether it falls within acceptable limits (e.g., within ±20% of the response without interference).

Threshold for Selectivity:

  • Define a threshold for acceptable interference. If the response change is within this threshold, the interference is considered negligible.

Reporting:

  • Summarize the results of the selectivity assessment in the bioanalytical validation report.
  • Document the interfering substances tested, the concentrations used, and the impact on Drug Y measurement.

Conclusion:

The selectivity assessment demonstrates whether the bioanalytical assay can accurately measure Drug Y in the presence of potential interfering substances commonly found in plasma. If the assay's accuracy and precision remain within acceptable limits in the presence of these interferences, it confirms that the assay is selective for measuring Drug Y.

Labels:

Popular posts from this blog

Human Genome Editing: FDA Draft Guidance Summary

Consideration for Developing Gene Editing Product  1. Genome Editing Methods: Genome editing can be achieved through nuclease-dependent or nuclease-independent methods. Nuclease-dependent methods involve introducing site-specific breaks in DNA using technologies like zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), modified-homing endonucleases, and CRISPR-associated (Cas) nucleases. These breaks can lead to modification of the DNA sequence at the cleavage site. Nuclease-independent methods can change DNA sequences without cleaving the DNA and include techniques like base editing and synthetic triplex-forming peptide nucleic acids. The choice of GE technology should consider factors such as the mechanism of action, the ability to target specific DNA sequences, and the potential to optimize components for efficiency, specificity, or stability. 2. Type and Degree of Genomic Modification: Different GE approaches rely on DNA repair pathways such a...
Read more

Stem loop RT-PCR for Detection of siRNA in Animal Tissues

Step Loop RT-PCR for Detection of Small Interfering RNA (siRNA) The recent publications described a novel used the novel method for the detection of siRNAs using a TaqMan®-based approach. This approach utilizes similar strategy that has been used for microRNA detection. The approach is illustrated in below.  In brief, the RT step occurs in the presence of a stem-loop RT primer that is complementary to the last 6–10 bases of the 3′ end of the antisense strand of the target siRNA. The stem-loop primer contains an additional universal sequence at the 5′ end that facilitates a TaqMan-based detection strategy in the subsequent qPCR step. As in the case of microRNA, the forward primer for qPCR is sequence-specific for the target siRNA. For sequence compositions that yield a low predicted melting temperature (Tm), the forward primer is designed as a tailed primer to help increase Tm. Stem Loop PCR for SiRNA Detection Step 1: Preparation of liver and plasma samples for the quanti...
Read more

Stem-Loop PCR for siRNA

 Stem-loop PCR is a method often used for detecting and quantifying small RNAs, such as siRNA or miRNA, which are typically difficult to amplify directly due to their short lengths. The method involves the design of a stem-loop reverse transcription (RT) primer, which enhances specificity and stability of the short RNA during the RT-PCR process, allowing for sensitive detection and quantification of the siRNA. Here’s a detailed guide to how stem-loop PCR can be applied to siRNA detection: Key Steps in Stem-Loop PCR for siRNA Designing the Stem-Loop RT Primer : Structure : The stem-loop RT primer consists of a loop region flanked by complementary sequences on either side (the "stem"), which will fold back on itself to form a hairpin structure. Specific Binding Region : A short sequence complementary to the 3’ end of the siRNA is added at the end of the stem-loop primer to ensure specific binding to the siRNA target. Stabilization : The loop structure helps prevent primer-dimer...
Read more

Allometric scaling in AAV gene therapy dose estimation

 Allometric scaling in AAV gene therapy dose estimation is crucial for translating effective and safe doses from animal models to humans. Since AAV dosing often involves high viral vector concentrations, proper dose scaling is essential to minimize adverse effects and optimize therapeutic outcomes. Here’s a breakdown of how allometric scaling is applied in AAV gene therapy dosing and the considerations involved: 1. Concept of Allometric Scaling Allometric scaling is a method of adjusting drug doses across species based on body size, physiology, and metabolism. It is especially useful in biologics and gene therapies where the pharmacokinetics and pharmacodynamics are more complex than small-molecule drugs. For AAV vectors, dosing is commonly scaled by body weight (e.g., vector genomes [vg] per kilogram) or body surface area (BSA), as these parameters can approximate dose distribution and vector exposure across different species. 2. Standard Scaling Approaches Body Weight Scaling (mg...
Read more

Cell-Mediated Immunity in AAV Gene Therapy

Cell-mediated immunity (CMI) plays a significant role in the effectiveness and safety of AAV (Adeno-Associated Virus) gene therapy. Understanding the impact of CMI is crucial for optimizing therapeutic outcomes and managing potential adverse effects. Here’s a detailed overview of the impact of CMI on AAV gene therapy: 1. Mechanisms of Cell-Mediated Immunity in AAV Gene Therapy T-Cell Activation : After administration of an AAV vector, T cells can recognize the AAV capsid proteins or the transgene product as foreign antigens, leading to their activation. This can involve both CD4+ helper T cells and CD8+ cytotoxic T cells. Cytokine Production : Activated T cells produce cytokines (e.g., IFN-γ, TNF-α) that can enhance the immune response. These cytokines can influence the activation and proliferation of other immune cells, including B cells and macrophages. 2. Impact on Efficacy of AAV Gene Therapy Enhanced Antigen Presentation : CMI can improve the presentation of transgene-derived anti...
Read more